Colorectal Cancer | Norton Healthcare

Indication: Colorectal Cancer

A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer

Deficient DNA Mismatch Repair Metastatic CRC

Sub-indication: DNA Mismatch-Repair-Deficient Metastatic Colorectal Adenocarcinoma

Line of Therapy: First line mFOLFOX6/bevacizumab combination therapy with or without atezolizumab vs atezolizumab monotherapy

Drug Study

Principal Investigator: Michael Driscoll, M.D.
Norton Cancer Institute

Sponsor: NRG Oncology

Learn more at

Email for more information:

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.